Surfactin Bacterial Antiviral Lipopeptide Blocks In Vitro Replication of SARS-CoV-2

Despite great efforts have been made worldwide, the coronavirus disease 19 (COVID-19) still has not a definitive cure, although availability of different vaccines are slowing down transmission and severity. It shown that surfactin, cyclic lipopeptide produced by Bacillus subtilis, is molecule able to counteract both SARS-CoV-1, MERS-CoV HCoV-229E coronaviruses. In this study potential antiviral activity surfactin against severe acute respiratory syndrome 2 (SARS-CoV-2) was tested in vitro cellular model infection. Our results show h treatment with reduce SARS-CoV-2 infectivity on Vero E6 cells at 24 after 7 days from viral inoculation, probably impairing membrane integrity. Moreover, concentrations used our experimental settings, cytotoxic. We suggest as new SARS-CoV-2, be employed least disinfectant.